Friday, 27 December 2013

Takeda Announces Termination of Fasiglifam (TAK-875) Development

Takeda Pharmaceutical Company Limited (Takeda) announced that it has decided voluntarily to terminate the development activities for fasiglifam (TAK-875), an investigational treatment for type 2 diabetes, due to concerns about liver safety (Takeda)

Bardoxolone Methyl in Type 2 Diabetes and Stage 4 Chronic Kidney Disease

Among patients with type 2 diabetes mellitus and stage 4 chronic kidney disease, bardoxolone methyl did not reduce the risk of ESRD or death from cardiovascular causes. A higher rate of cardiovascular events with bardoxolone methyl than with placebo prompted termination of the trial (New England Journal of Medicine)

Tuesday, 24 December 2013

Early Microvascular Changes with Loss of the Glycocalyx in Children with Type 1 Diabetes

Our results disclose the glycocalyx as a possible monitoring measurement for earlier detection of diabetic microangiopathy and may provide a basis for new therapeutic strategies aiming at protection or restoration of the glycocalyx (The Journal of Pediatrics)

Erythropoietin, a novel repurposed drug: An innovative treatment for wound healing in patients with diabetes mellitus

In this review, the mechanism of EPO's action in skin wound healing is reviewed, and its potential for treating acute and chronic skin wounds and stimulating tissue regeneration in diabetic patients is discussed (Wound Repair and Regeneration)

Friday, 20 December 2013

Diabetes Community Health Profiles

The Diabetes Community Health Profiles bring together a wide range of data on diabetes in adults into a single source for the purposes of benchmarking. The tool allows you to download a diabetes profile for each area in England (YHPHO)

National Paediatric Diabetes Audit Report 2011-12

Care processes and outcomes (RCPCH)

Diabetes UK State of the Nation report 2013 

This report highlights the problem that quality of care for diabetics is uneven throughout England. It notes that diabetes care is adequately funded but that the focus of the spending should be on prevention rather than treatment (Diabetes UK)

Thursday, 19 December 2013

Altered Spontaneous Brain Activity in Type 2 Diabetes: A Resting-State Functional MRI Study

The abnormalities of spontaneous brain activity reflected by ALFF and ReHo measurements in the absence of structural changes in T2DM patients may provide insights into the neurological pathophysiology underlying diabetes-associated cognitive decline (Diabetes)

Proinsulin-Transferrin Fusion Protein as a Novel Long-acting Insulin Analogue for the Inhibition of Hepatic Glucose Production

ProINS-Tf exhibited a slow, but sustained, in vivo hypoglycemic efficacy and long plasma half-life. Thus, ProINS-Tf fusion protein can potentially be administered as a prodrug with sustained Tf-mediated activation and selectivity in inhibiting hepatic glucose production (Diabetes)

Bristol-Myers Squibb - Sale of Its Diabetes Business

Bristol-Myers Squibb Company announce that it has signed an agreement to sell its global diabetes business that was part of its collaboration with AstraZeneca (Bristol-Myers Squibb)

Midlife type 2 diabetes and poor glycaemic control as risk factors for cognitive decline in early old age

The risk of accelerated cognitive decline in middle-aged patients with type 2 diabetes is dependent on both disease duration and glycaemic control (The Lancet Diabetes & Endocrinology)

Tuesday, 17 December 2013

Diabetes drugs affect hearts of men, women differently

In particular, the commonly prescribed diabetes drug metformin had positive effects on heart function in women but not in men, who experienced a shift in metabolism thought to increase the risk of heart failure (Washington University School of Medicine)

The Role of Autophagy in the Pathogenesis of Diabetic Nephropathy

In this review, we discuss new findings showing the relationships between autophagy and diabetic nephropathy and suggest the therapeutic potential of autophagy in diabetic nephropathy (Journal of Diabetes Research)

Monday, 16 December 2013

Effect of Glargine Insulin Delivery Method (Pen-Device vs. Vial-Syringe) on Glycemic Control and Patient Preferences in Patients with Type 1 and Type 2 Diabetes

Patients switching to glargine pen achieved lower HbA1c at 6 months of follow-up. Patients in both groups overwhelmingly preferred glargine pens over vial-syringe (Endocrine Practice)

Effect of once-daily insulin detemir on oral antidiabetic drug (OAD) use in patients with type 2 diabetes

Discontinuation (or switching) of OADs at the time of insulin initiation appears to be governed principally by concerns about hypoglycaemia and weight. HbA1c improvements were smaller in patients discontinuing OADs at the time of insulin initiation and may be associated with insufficient insulin titration (Journal of Clinical Pharmacy and Therapeutics)

Saxagliptin (Onglyza®) 2.5 mg and 5 mg film-coated tablets

Saxagliptin (Onglyza®) is recommended as an option for use within NHS Wales for the treatment of adult patients aged 18 years and older with type 2 diabetes mellitus to improve glycaemic control as triple oral therapy in combination with metformin plus a sulphonylurea when this regimen alone, with diet and exercise, does not provide adequate glycaemic control (All Wales Medicines Strategy Group)

Sunday, 15 December 2013

Bristol, AstraZeneca withdraw diabetes drug in Germany

Bristol-Myers Squibb and AstraZeneca said they would pull a new diabetes drug from the German market because they had failed to agree on a price with a body of medical insurers. The decision to stop marketing oral drug dapagliflozin in Germany comes just a day after it was endorsed by an advisory panel to the U.S. Food and Drug Administration (Reuters)

Saturday, 14 December 2013

This Time, FDA Panel Endorses Diabetes Drug Dapagliflozin

A US Food and Drug Advisory (FDA) panel has voted 10 to 1 in favor of approval for AstraZeneca and Bristol-Myers Squibb's diabetes drug dapagliflozin (Medscape)

Thursday, 12 December 2013

The 3rd national diabetes inpatient conference, innovations in diabetes inpatient care

Wednesday 29 January 2014 Venue: Royal Society Of Medicine, 1 Wimpole Street, London. Also call for abstracts

Silent myocardial ischemia detected by single photon emission computed tomography (SPECT) and risk of cardiac events among asymptomatic patients with type 2 diabetes

SMI detected by SPECT is associated with increased risk of cardiac death, all-cause mortality, and non-fatal cardiac events in T2DM patients without overt cardiac symptoms. Advanced intervention procedures including intensive drug management should be implemented to reduce the risk of cardiac events for SMI-positive T2DM patients

Glucose-dependent Insulinotropic Polypeptide: Blood Glucose Stabilizing Effects in Patients with Type 2 diabetes

In patients with T2DM, GIP counteracts insulin-induced hypoglycemia – most likely through a predominant glucagonotropic effect. In contrast, during hyperglycemia, GIP increases glucose disposal through a predominant effect on insulin release (Journal of Clinical Endocrinology & Metabolism)

Laparoscopic adjustable gastric banding and progression from impaired fasting glucose to diabetes

In obese people with IFG, weight loss after LAGB is associated with a substantially reduced risk of progressing to diabetes over =4 years. Bariatric surgery may be an effective diabetes prevention strategy in this population (Diabetologia)

Treatment intensification with stepwise addition of prandial insulin aspart boluses compared with full basal-bolus therapy (FullSTEP Study): a randomised, treat-to-target clinical trial

Stepwise prandial insulin intensification provides glycaemic control non-inferior to a full basal-bolus regimen after 32 weeks, with significantly lower hypoglycaemia risk and better patient satisfaction (The Lancet Diabetes & Endocrinology)

Wednesday, 11 December 2013

What happens when patients know more than their doctors? Experiences of health interactions after diabetes patient education: a qualitative patient-led study

Patients who have in-depth knowledge of their condition encounter problems when their expertise is seen as inappropriate in standard healthcare interactions, and expertise taught to patients in one branch of medicine can be considered non-compliant by those who are not specialists in that field (BMJ Open)

Tuesday, 10 December 2013

vildagliptin (Galvus® ) is accepted for restricted use within NHS Scotland
State of the Nation 2013

This year’s report shows that diabetes continues to be a major challenge for the NHS. It is still a huge drain on resources, quality of care still depends on where you live, and the crisis is still not being taken seriously (Diabetes UK)

Autonomous exercise game use improves metabolic control and quality of life in type 2 diabetes patients

In this trial a low-threshold intervention with the interactive exercise game Wii Fit Plus was able to motivate T2DM patients to improve physical activity, glucometabolic control and quality of life (BMC Endocrine Disorders)

Monday, 9 December 2013

Quantitative Estimation of Insulin Sensitivity in Type 1 Diabetic Subjects Wearing a Sensor Augmented Insulin Pump

This new index correlates well with the reference oral minimal model estimate of insulin sensitivity. The knowledge of patient-specific insulin sensitivity and its diurnal variation can help in optimizing insulin therapy in type 1 diabetes and could also inform the next generation closed-loop control systems (Diabetes Care)

Proliferative retinopathy in type 1 diabetes is associated with cerebral microbleeds, which is part of generalized microangiopathy

In PDR patients cerebral microbleeds prevalence was higher and seems part of generalized microangiopathy that may affect the skin and the brain (Diabetes Care)

Thursday, 5 December 2013

New data support flexibility in timing of administration for Sanofi's lixisenatide

The results of a 24-week Phase IIIb clinical study showed that lixisenatide met the primary endpoint of non-inferiority in blood sugar lowering (HbA1c) when administered either before breakfast or the main meal of the day. These results indicate that lixisenatide can effectively lower blood sugar at either time of administration (Sanofi)

GAD-treatment of children and adolescents with recent-onset Type 1 diabetes preserves residual insulin secretion after 30?months

Treatment with two doses of GAD-alum in children and adolescents with recent-onset T1D shows no adverse events and preserves residual insulin secretion (Diabetes/Metabolism Research and Reviews)

Assessing the cost-effectiveness of Type 1 diabetes interventions: the Sheffield Type 1 Diabetes Policy Model

This paper describes the conceptual modelling, model implementation and model validation of the Sheffield Type 1 Diabetes Policy Model (version 1.0), developed through funding by the UK National Institute for Health Research as part of the Dose Adjustment for Normal Eating research programme (Diabetic Medicine)

Wednesday, 4 December 2013

Admissions avoidance and diabetes

Guidance for clinical commissioning groups and clinical teams (JBDS – IP)

Pathophysiology and treatment of type 2 diabetes

Perspectives on the past, present, and future (The Lancet)

Co-Stimulation Modulation with Abatacept in Patients with Recent-Onset Type 1 Diabetes: Follow-Up One Year After Cessation of Treatment

Co-stimulation modulation with abatacept slowed decline of beta-cell function and improved HbA1c in recent-onset T1DM. The beneficial effect was sustained for at least one year after cessation of abatacept infusions, or three years from T1DM diagnosis (Diabetes Care)

Tuesday, 3 December 2013

Sanofi Announces New Phase 3 Results for Investigational New Insulin U300

We are encouraged by these results which suggest that U300 could be a viable treatment option for a wide range of people with type 1 and type 2 diabetes (Sanofi)

Largest Global Survey Investigating Early Type 2 Diabetes Conversations 

Launched by Boehringer Ingelheim and Eli Lilly and Company in Partnership with the International Diabetes Federation. More than 10,000 people with self-reported and diagnosed type 2 diabetes and more than 6,500 treating-physicians from 26 countries to take part in new survey (Boehringer Ingelheim)

Towards metabolic biomarkers of insulin resistance and type 2 diabetes: progress from the metabolome

These biomarkers will help to improve research and management of diabetes. In particular, several biomarkers identified could be used for early identification of diabetes risk (The Lancet Diabetes & Endocrinology)

Limited recovery of ß-cell function after gastric bypass despite clinical diabetes remission

These data show that ß-cell dysfunction persists after RYGBP, even in patients in clinical diabetes remission. This impairment can be rescued by oral glucose stimulation, suggesting that RYGBP leads to an important gastrointestinal effect, critical for improved ß-cell function after surgery (Diabetes)

Defining the Role of GLP-1 in the Enteroinsulinar Axis in Type 2 Diabetes (T2D) utilizing DPP-4 inhibition and GLP-1-Receptor Blockade

In this cohort of diabetic patients with a substantial incretin effect, GLP-1 contributed about 50% to the insulin excursion after an OGT both with and without DPP-4 inhibition. Thus, a significant DPP-4 sensitive glucose lowering mechanism contributes to glycemic control in diabetic patients that may be not mediated by circulating GLP-1 (Diabetes)

Monday, 2 December 2013

Canagliflozin: a novel treatment option for type 2 diabetes

In this manuscript we review canagliflozin and its potential role in management of type 2 diabetes mellitus (Drug Design, Development and Therapy)

Transcutaneous Oxygen Pressure Measurement in Diabetic Foot Ulcers: Mean Values and Cut-Point for Wound Healing

TcPO2= 40 mmHg was associated with diabetic foot ulcer healing, but a TcPO2= 10 mmHg was associated with failure of wound healing. We found that a cut-point of 25 mmHg was most predictive of diabetic foot ulcer healing (Journal of Wound, Ostomy and Continence Nursing)